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BACKGROUND: Sudden cardiac arrest is the leading mode of death in the United States. Epilepsy affects 1% of Americans; 
yet epidemiological data show a prevalence of 4% in cases of sudden cardiac arrest. Sudden unexpected death in epilepsy 
(SUDEP) may share features with sudden cardiac arrest. The objective of this study was to report autopsy and genomic find-
ings in a large cohort of SUDEP cases.
METHODS AND RESULTS: Mayo Clinic Sudden Death Registry containing cases (ages 0– 90 years) of sudden unexpected and un-
explained deaths 1960 to present was queried. Exome sequencing performed on decedent cases. From 13 687 cases of sudden 
death, 656 (4.8%) had a history of seizures, including 368 confirmed by electroencephalography, 96 classified as SUDEP, 58 as 
non- SUDEP, and 214 as unknown (insufficient records). Mean age of death in SUDEP was 37 (±19.7) years; 56 (58.3%) were male; 
65% of deaths occurred at night; 54% were found in bed; and 80.6% were prone. Autopsies were obtained in 83 cases; bystander 
coronary artery disease was frequently reported as cause of death; nonspecific fibrosis was seen in 32.6% of cases, in structurally 
normal hearts. There were 4 cases of Dravet syndrome with pathogenic variants in SCN1A gene. Using whole exome sequencing in 
11 cases, 18 ultrarare nonsynonymous variants were identified in 6 cases including CACNB2, RYR2, CLNB, CACNA1H, and CLCN2.
CONCLUSIONS: This study examined one of the largest single- center US series of SUDEP cases. Several cases were reclas-
sified as SUDEP, 15% had an ECG when alive, and 11 (11.4%) had blood for whole exome sequencing analysis. The most 
frequent antemortem genetic finding was pathogenic variants in SCN1A; postmortem whole exome sequencing identified 18 
ultrarare variants.
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Sudden cardiac arrest is the leading cause of death in the United States, claiming 340 000 lives each year, including thousands under the age of 35 who 
tragically die suddenly and unexpectedly.1– 3 Epilepsy 
affects 1% of Americans, yet epidemiological data of 
victims of sudden cardiac arrest show a prevalence 
of preexisting epilepsy of 4%, suggesting these cases 
of sudden cardiac arrest could instead be sudden 
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unexpected death in epilepsy (SUDEP).1– 3 More than 
two- thirds of witnessed arrests in people with epilepsy 
(PWE) have no preceding seizure activity4– 6 and a dis-
proportionate 60% of SUDEP fatalities occur during 
sleep, implicating cardiac arrhythmia and possible un-
diagnosed sleep apnea as possible contributors.7– 11
SUDEP can occur at any age, including infants and 
children, but those between the ages of 15 to 40 years 
are at greatest risk. The young age of victims makes 
SUDEP a highly visible, emotive, and tragic event, and 
in potential years of life lost it is the leading cause of 
death after stroke.12– 15
Although the pathophysiology of SUDEP is unsolved, 
postictal brain shutdown with electroencephalography 
suppression, depression of respiratory function, sym-
pathetic activation, catecholamine surges, impaired 
heart rate variability,16,17 medullary respiratory dysfunc-
tion, neurogenic pulmonary edema, antiepileptic drug 
(AED) polytherapy, and ion channel dysfunction have 
all been implicated.18– 20 Ion channelopathies such as 
catecholaminergic polymorphic ventricular tachycar-
dia, Brugada syndrome, and long- QT syndromes, can 
present with seizures, syncope, and arrhythmia.21– 41 
Several experts have proposed that "arrhythmogenic 
epilepsy" due to genetic or acquired ion channel 
disease (as a result of repeated seizures) could be 
predominant or contributing pathophysiological mech-
anisms in SUDEP.18,42,43
SUDEP is defined as a “non- traumatic, non- 
drowning, unexpected (witnessed or unwitnessed) 
death of an otherwise healthy PWE, which may or 
may not occur with evidence of an acute seizure (ex-
cluding status epilepticus).”13,14 International guidelines 
have existed for many years recommending compre-
hensive investigation of PWE decedents to determine 
whether a SUDEP or non- SUDEP mechanism (such as 
drowning, trauma, or suicide) may be responsible for 
death.44,45
SUDEP guidelines have recommended specialist 
neuropathologist input to examine brain tissue, analo-
gous to better established sudden cardiac death (SCD) 
autopsy guidelines that mandate performance in each 
case of drug and toxin screening, heart examination by 
cardiac pathologists, and blood storage for postmor-
tem genetic testing.46,47 Autopsy series in PWE have 
shown inconsistent systematic and comprehensive 
assessment,48– 51 prompting the publication of a re-
cent position paper on the “Recommendations for the 
Investigation and Certification of Deaths in PWE” by 
the National Association of Medical Examiners, which 
included an expert panel of pathologists, medical ex-
aminers, epileptologists, and cardiologists.52
The aims of this study were to report characteris-
tics of a large cohort of SUDEP cases from a tertiary 
care academic medical center, review consistency of 
evaluation of cases of SUDEP, and perform adjunct 
postmortem next generation whole exome sequenc-
ing (WES) to identify ion- channel, arrhythmia, epilepsy- 
related, and sudden death- related variants.
METHODS
This study was approved by the institutional review 
board of The Mayo Clinic Rochester, MN; and informed 
consent was obtained.
Mayo Clinic Sudden Death Registry
For the purpose of this study, we built the MCSDR 
(Mayo Clinic Sudden Death Registry), which contains all 
cases (ages 0– 90 years and both sexes) of sudden un-
expected and unexplained deaths from 1960 to present 
that have been verified by multisource ascertainment of 
postmortem reports, county medical examiner’s office 
CLINICAL PERSPECTIVE
What Is New?
• Sudden unexpected death in epilepsy is still not 
well understood and it can overlap with sudden 
cardiac arrest in many cases.
• We collected one of the largest cohorts of sud-
den unexpected death in epilepsy cases with 
the aim to perform postmortem autopsy and 
antemortem- postmortem genetic testing with 
any available DNA.
• The most frequent pathogenic variants reported 
were in the SCN1A gene related to Dravet syn-
drome and we found 18 ultrarare variants of un-
determined significance in 11 cases.
What Are the Clinical Implications?
• Our findings suggest a serious gap in knowl-
edge of the genetic associations of sudden un-
expected death in epilepsy because of the lack 
of sufficient blood and tissue samples to be 
analyzed and the urgent need for a large- scale, 
multicenter, cooperative prospective sudden 
death registry in people with epilepsy to yield 
analyzable samples and to elucidate possible 
causative variants.
Nonstandard Abbreviations and Acronyms
DrS Dravet syndrome
PWE people with epilepsy
SCD sudden cardiac death
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(or coroner) reports, validated death certificate data, and 
the emergency medical services (EMS) data (n=13 687; 
Figure 1). This includes SCD, sudden unexplained death 
syndromes, sudden infant death syndrome, and out- of- 
hospital cardiopulmonary arrest cases.
The definition of SCD is based on the World Health 
Organization criteria: sudden and unexpected death 
occurring within 60  minutes of the onset of symp-
toms (if witnessed) and within 24  hours if observed 
alive and symptom free (if nonwitnessed). Mayo Clinic 
Figure 1. Case selection from the Mayo Clinic Sudden Death Registry.
Multisource case ascertainment was used to build the registry including autopsy reports, medical examiner and coroner cases, death 
certificate searches using validated criteria, and EMS data. Cases were then selected based on a history of seizures or syncope 
and then adjudicated to determine if there was a diagnosis of epilepsy. Cases of secondary seizures, even if a sudden death event 
occurred, were excluded. The final cohort was then classified into SUDEP categories. EMS indicates emergency medical service; Hx, 
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Rochester performs autopsies on cases of sudden 
unexpected or unexplained death or deaths that oc-
curred rapidly before a diagnosis could be accurately 
determined, or those occurring in the setting of re-
cent medical intervention or surgery. All autopsies for 
the local area of Olmsted County, MN are conducted 
here, as are those performed for neighboring counties 
and the states of Minnesota, Wisconsin, Iowa, and 
New York.
Using the Minnesota Death Tapes, a statewide elec-
tronic record of death certificates, all potential sudden 
deaths cases have been identified with the use of val-
idated search criteria (n=98 183 from January 1, 1960 
to December 31, 2016).53– 55 Given that medical records 
are available for >90% of Olmsted County residents at 
Mayo Clinic Rochester, we included only those with an 
Olmsted County address of residence (n=4745). Gold 
Cross is the sole EMS provider for Olmsted County 
and the surrounding area. Since January 1, 1990, a 
record of all arrests attended by the EMS has been 
maintained and these data were also incorporated into 
the MCSDR.
Inclusion and Exclusion Criteria
We screened the MCSDR for all cases with keywords 
“seizure” or “epilepsy” between the dates of January 1, 
1960 to December 31, 2016. Cases with the following 
were excluded: known malignancy, intracranial hem-
orrhage (extradural, subdural, subarachnoid, intraven-
tricular or intraparenchymal), suicide, homicide, and 
status epilepticus.
Each case was then reviewed in detail, including 
paper and electronic records, death certificates, obitu-
aries, autopsy reports, medical examiner reports, and 
EMS data, where available. A diagnosis of epilepsy was 
made based on International League Against Epilepsy 
criteria based on 1 or more of the following 3 criteria: 
(1) at least 2 unprovoked (or reflex) seizures occurring 
>24  hours apart; (2) 1 unprovoked (or reflex) seizure 
and a probability of further seizures; and (3) diagnosis 
of an epilepsy syndrome.56
SUDEP Adjudication
Deaths were classified as non- SUDEP when there 
was clearly an alternative cause of death such as 
trauma, drowning, drug overdose, suicide or homi-
cide or as SUDEP cases as follows: (1) definite if the 
autopsy did not reveal a cause of death; (2) definite- 
plus where an autopsy was performed and there 
was an alternative contributing factor; (3) probable 
in the absence of an autopsy but other supporting 
evidence; (4) possible in the absence of an autopsy 
and if there was a competing cause of death; and (5) 
unknown if there were no autopsy, no witness, and 
limited records.13,14
Case Note Abstraction
Medical, EMS, and autopsy reports were comprehen-
sively and systematically reviewed and abstracted to 
an electronic case report form in REDCap (Vanderbilt 
University) hosted at Mayo Clinic.57 REDCap (Research 
Electronic Data Capture) is a secure, web- based appli-
cation designed to support data capture for research 
studies, providing (1) an intuitive interface for validated 
data entry, (2) audit trails for tracking data manipulation 
and export procedures, (3) automated export proce-
dures for seamless data downloads to common statis-
tical packages, and (4) procedures for importing data 
from external sources.
The following variables were abstracted: (1) demo-
graphics; (2) interviews with witnesses/family mem-
bers; (3) emergency- medical response team data; (4) 
medical records (including history of seizures, past 
medical history, medication use, smoking, alcohol and 
use of drugs of abuse, electrocardiography, electroen-
cephalography, and imaging of the brain and heart); (5) 
coroner’s report including circumstances of death; (6) 
autopsy report including gross macroscopic and mi-
croscopic evaluation of the brain, heart, and lungs; and 
(7) toxicology screen. All entries were rechecked by a 
second abstractor and then 10% randomly checked to 
ensure consistency with an error rate of <2%.
Postmortem Next Generation Whole 
Exome Sequencing
DNA Isolation
Genomic DNA was isolated from autopsy whole blood 
or frozen tissue using the Gentra Puregene Blood Kit 
(Qiagen, Germantown, MD) following the manufactur-
er’s protocol.
Whole Exome Next- Generation DNA Sequencing
Genomic DNA samples were submitted to Mayo 
Clinic’s Advanced Genomics Technology Center for 
WES. The Bravo liquid handler and Aligent’s proto-
col was used to prepare paired- end libraries, and 
DNA was fragmented using a Covaris E210 sonicator. 
Agencourt AMPure SPRI beads were used to purify the 
constructs. SureSelect forward and Agilent SureSelect 
ILM Pre- Capture Indexing reverse primers were used 
to enrich the DNA fragment libraries, which were ana-
lyzed with Agilent Bioanalyzer DNA 1000 chip.
Exome capture was performed with the SureSelect 
XT Human All Exon V5 plus UTR Target Enrichment 
System (Agilent, Santa Clara, CA). Dynal Dynabeads 
MyOne Streptavidin T1 captured the DNA:RNA hy-
brids, and Agencourt Ampure XZP beads eluted DNA 
from the beads, which were amplified with Agilent Sure 
Select Post- Capture Indexing forward and Index PCR 
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was completed with Illumina HiSeq 2000 platform 
(San Diego, CA) and TruSeq SBS sequencing kit V3 
reagents.
Variant Filtering and Pathogenicity 
Assessment
Following WES, single nucleotide variants and inser-
tion/deletions were filtered to identify variants that 
followed either a dominant or recessive inheritance 
pattern using Ingenuity Variant Software (Qiagen, 
Redwood City, CA). All variants within 71 epilepsy-
 (from Bagnall),58 5 central hypoventilation- (from 
Bagnall),58 and 90 genetic heart disease (long- QT 
syndrome, catecholaminergic polymorphic ventricular 
tachycardia, Brugada syndrome, hypertrophic car-
diomyopathy, dilated cardiomyopathy, and arrhythmo-
genic right ventricular cardiomyopathy)— susceptibility 
genes (Table  S1) were first filtered for a call quality 
score ≥20 and a read depth ≥10. Only nonsynonymous 
variants (NSV, ie, amino acid altering: missense, non-
sense, splice- error, frameshift insertion/deletions, or 
in- frame insertion/deletions) were considered poten-
tially pathogenic.
For the dominant model, only ultrarare variants 
(minor allele frequency [MAF] ≤0.00005) (1:20  000 
alleles) in Genome Aggregation Database (gnomAD; 
http://gnomad.broad insti tute.org) were considered. 
Variants with a MAF >0.00005 in any ethnic group of 
gnomAD were excluded, unless observed only once in 
that ethnic group.
For the recessive inheritance model, only rare 
(MAF ≤0.01 in gnomAD) variants present as homozy-
gotes were considered. Variants with a homozygous 
frequency >0.0001 in gnomAD were excluded from 
analysis. Given that parental DNA was unavailable to 
confirm that variants were in trans (on opposite alleles), 
compound heterozygotes (2 unique mutations in the 
same gene) were excluded from the recessive analy-
sis. A comparison of yield of NSVs for both the dom-
inant and recessive model was performed for all 166 
sudden death- susceptibility genes.
The American College of Medical Genetics and 
Genomics (ACMG) and Association for Molecular 
Pathology standards and guidelines for the interpreta-
tion of sequence variants were used to classify identi-
fied variants as pathogenic (P), likely pathogenic (LP), 
or variant of uncertain significance.59 Automatic variant 
classification was performed using InterVar, a freely 
available web- based bioinformatics software tool for 
clinical interpretation of genetic variants by the ACMG/
Association for Molecular Pathology 2015 guideline.60
Statistical Analysis
All calculations were performed using SAS® or JMP 
13.0 (SAS Institute, Cary, NC). Continuous variables 
are reported via means with SD; categorical variables 
are reported as frequencies and percentages with as-
sociated CIs. All continuous variables were tested for 
normality and appropriate parametric tests used (eg, 
Shapiro- Wilk or Kolmogorov- Smirnov tests), as appro-
priate given distributional assumptions. For categorical 
variables, chi- square tests or Fisher’s exact tests, and 
for nonnormally distributed data the appropriate non-
parametric tests that met the nonparametric assump-
tions were used instead. For variant calling, Fisher’s 
exact tests were performed to determine statistical sig-
nificance between 2 groups. All tests are 2 sided with 
an a priori comparison- wise α level of <0.05. The first 
author had full access to all the data in the study and 
takes responsibility for its integrity and the data analysis.
RESULTS
A keyword search for “seizure” or “epilepsy” identi-
fied 656 (4.8%) of potential cases from the MCSDR of 
whom 288 (43.9%) either did not have epilepsy or had 
insufficient records to firmly establish diagnosis of epi-
lepsy before sudden death. Many cases had secondary 
seizures, such as anoxic seizures following prolonged 
cardiac arrest times, seizures related to electrolyte ab-
normalities, seizures in the context of sepsis, menin-
goencephalitis, or toxins including alcohol- related. The 
remaining 368 were confirmed to have epilepsy, either 
current or with a past diagnosis of epilepsy that is no 
longer present. Of these, 214 (66% male, mean age at 
death of 64.7±18.4, years) had only death certificate data 
and insufficient records to be classified as SUDEPs.
Where data were available, the majority had SCD 
events owing to acute myocardial infarction or arrhyth-
mia in the presence of established heart failure. These 
were classified as unknown given the lack of informa-
tion, it is unclear if they were possible SUDEPs. Of par-
ticular note, there was a single case of a 17- year- old girl 
with Aicardi syndrome (malformation syndrome with 
partial or complete absence of the corpus callosum 
associated with refractory seizures) who died at home, 
and a death certificate stated, “natural causes.” No 
specific details or an autopsy were available regard-
ing the death, and hence our rationale was to classify 
this case as unknown, although it could possibly have 
been SUDEP.
Fifty- eight cases (15.8%) were unequivocal non- 
SUDEPs with causes including drowning, trauma, and 
poisoning. In addition, 96 cases (26.1%) were classi-
fied as definite, definite- plus, probable, and possible 
SUDEP cases (Figure 2).
SUDEP Versus Non- SUDEP
The main clinical findings in the SUDEP group are 
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was 36.9 (±19.6) years and 57.5% were men (Table 2). 
The mean age of non- SUDEP cases was significantly 
higher at 53.0 (±18.3) years (P<0.0001), with a similar 
male majority (69.0% men, P=0.1606). There was no 
difference in body mass index in SUDEP versus non- 
SUDEP cases (P=0.2774).
Multisource Ascertainment
The records available for each class of SUDEP are 
summarized (Table  S2). There were no emergency 
medical records for any of the decedents of SUDEP, 
either because an electronic database was only main-
tained from 1990, most of the cases died suddenly 
and unexpectedly, with electroencephalography- 
confirmed epilepsy without postmortem or at the 
scene investigation, tended to be before the 1990s; 
deaths occurred outside of Olmsted County, MN, 
or as in the majority, decedents were already found 
dead.
SUDEP Cases
The age range of decedents of SUDEP was 1 to 
84 years with a mean (±SD) age of 37 (±19.7) years, 
and 56 (58.3%) were male. The majority were White 
(64%) and from the midwestern United States 
(95.8%). In 28.1%, ethnicity could not be accurately 
determined, particularly for cases with only paper 
records (before 1995), where this information was 
not consistently recorded. The mean age at epilepsy 
onset was 21.2 (±17.2) years and ranged from shortly 
after birth to age 76 years. The mean time from the 
diagnosis of epilepsy to SUDEP was 16.9±13.7 years. 
Six cases from the older age group tended to have 
structural etiologies such as postischemic stroke or 
postsurgery seizures, classed as epilepsy and re-
quiring treatment.
Etiology of Epilepsy
Based on the classifications of International League 
Against Epilepsy, the etiology of epilepsy was unknown 
in the majority. Cases of alcohol- related seizures were 
excluded if clearly related to withdrawal and with oc-
casional frequency. However, patients with likely un-
derlying epilepsy who developed recurrent seizures in 
the absence of alcohol withdrawal or poisoning were 
included.
There were 4 cases of Dravet syndrome (DrS), 3 
of whom were classified as definite SUDEPs, and 
1 was classified as definite- plus SUDEP. One was 
a 3- year- old girl of Native American descent with a 
de novo pathogenic variant in SCN1A (p.Asn359Ser) 
who had a history of febrile seizures and medically 
refractory afebrile generalized tonic- clonic seizures 
and focal seizures. The patient had a witnessed car-
diopulmonary arrest with a prolonged downtime, and 
although the patient was resuscitated, there was ev-
idence of severe anoxic brain injury, and a decision 
was made to withdraw life support. The second case 
was a 2- year- old White boy with refractory myoclonic 
absence seizures and a de novo pathogenic variant in 
SCN1A (p.Arg101Gln). A 12- lead ECG showed QTc at 
rest of 416 ms, and echocardiogram demonstrated a 
structurally normal heart. The patient was found dead 
in his crib in the prone position, and an autopsy re-
vealed no abnormality. There were no significant find-
ings with the other 2 cases of DrS with pathogenic 
variants in SCN1A, One 8- year- old White boy with de 
novo pathogenic variant in SCN1A (p.Arg786Val) and 
a 2- year- old Hispanic girl with a pathogenic variant in 
SCN1A.
Circumstances Around Death
Only 15 (15.6%) SUDEP cases were witnessed, and 
the majorities of deaths occurred out of hospital, ei-
ther at home or work (Table 3). Only 13 (13.5%) had a 
clearly documented seizure at the time of SUDEP or 
in the preceding 24 hours, although in the majority of 
cases, the presence or absence of a seizure proximate 
to death was not clearly documented.
In 60 cases having sufficient data to determine 
time of death, 39 (65%) occurred during the nighttime 
hours. Of the 21 daytime deaths, 19 occurred at rest, 1 
during physical exercise, and 1 during emotional stress 
after receiving news of bereavement.
Of 35 cases with sufficient data regarding body 
location at time of death, 19 (54.3%) were found 
dead in bed, 4 (11.4%) were found on the bedroom 
floor, 4 (11.4%) were found on the bathroom floor, 2 
(5.7%) were found slumped in a couch or chair, and 
6 (17.1%) were found on the living room floor. In 31 
cases with sufficient data for the body position found 
at death, 25 (80.6%) were found in the prone position, 
Figure 2. Classification of deaths in people with epilepsy, 
based on SUDEP Task Force and expert recommendations 
into definite, definite- plus, probable, possible, and non- 
SUDEP.
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Table 1. Clinical Characteristics of the SUDEP Cohort Combined and by Sex
Variable Overall (n=96) Male sex (n=56) Female sex (n=40) P value
Demographics
From Midwest, n (%) 92 (95.8) 53 (94.6) 40 (97.6) 0.64
Resident of Olmsted County, MN 59 (61.5) 34 (56.7) 26 (43.3) 0.85
Race/Ethnicity, n (%)
White 61 (64) 38 (67.8) 23 (57.5) …
Native American or Alaska Native 1 (1) 0 (0) 1 (2.5) …
Asian 1 (1) 0 (0) 1 (2.5) …
Black 3 (3) 3 (5.4) 0 (0) …
Hispanic 0 (0) 0 (0) 0 (0) …
Native Hawaiian or Pacific Islander 0 (0) 0 (0) 0 (0) …
Mixed race 3 (3) 2 (3.6) 1 (2.5) …
Unknown or not disclosed 27 (28.1) 13 (23.2) 14 (35.0) …
Age at epilepsy onset
Mean±SD (range) y 21.2±17.2 (0– 76) 21.1±17.5 (0– 74) 21.3±17.0 (0– 76) 0.48
Age at SUDEP
Mean±SD (range) y 37.4±19.4 (2– 84) 37.3±17.8 (3– 80) 37.6±21.7 (2– 84) 0.47
Body mass index
Mean±SD (range), kg/m2 26.5±8.4 26.8±7.9 26.1±9.2 0.693
Duration of seizures
Mean±SD (range) y 15.8±13.02 (0– 57) 15.6±11.9 (0– 45) 16.0±14.5 (0– 57) 0.44
Recent onset (1– 2 y), n (%) 22 (23.0) 12 (21.0) 10 (25.0) …
Intermediate duration (3– 10 y), n (%) 20 (21.0) 11 (20.0) 9 (23.0) …
Chronic epilepsy (>10 y), n (%) 54 (56.0) 33 (59.0) 21 (53.0) …
Etiology of epilepsy
Epilepsy syndrome
Idiopathic 18 (18.7) 8 (14.2) 10 (25.0) …
Primary generalized epilepsy 8 (8.3) 3 (5.4) 5 (12.5) …
Juvenile myoclonic epilepsy 1 (1.0) 1 (1.8) 0 (0.0) …
Genetic syndromes
Dravet 4 (4.2) 2 (3.6) 1 (2.5) …
DiGeorge 0 (0.0) 0 (0.0) 0 (0.0) …
Down 0 (0.0) 0 (0.0) 0 (0.0) …
Structural/metabolic
Posttraumatic epilepsy 5 (5.3) 5 (8.9) 0 (0.0) …
Malformation of cortical development 7 (7.3) 5 (8.9) 2 (5.0) …
Tumors/operated structural lesions 6 (6.3) 5 (8.9) 1 (2.5) …
Temporal lobe epilepsy 3 (3.1) 0 (0.0) 3 (7.5) …
Metabolic 1 (1.0) 1 (1.8) 0 (0.0) …
Perinatal (ulegyria) 0 (0.0) 0 (0.0) 0 (0.0) …
Postinfarct 2 (2.1) 2 (3.6) 0 (0.0) …
Alcohol- related 5 (5.2) 2 (3.6) 3 (7.5) …
Immune- related 2 (2.1) 0 (0.0) 2 (5.0) …
Infectious 2 (2.1) 2 (3.6) 0 (0.0) …
Mixed 9 (9.4) 5 (8.9) 4 (10.0) …
Unclassified, n (%) 23 (23.9) 15 (26.8) 9 (22.5) …
Seizure types
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irrespective of location. Body location and position at 
the time of death were not recorded clearly in the re-
maining cases.
Alcohol, Smoking, and Antiepileptic Drugs
A history of alcohol abuse could not be determined in 66 
(68.8%) decedents. In the remaining 30, 10 (33%) had a 
history of alcohol dependence. Smoking status could not 
be determined in 70 (72.9%) cases, and of the remaining 
26, 11 (42.3%) were either former or current smokers. 
None of the patients took cardiovascular drugs, and in 
particular no decedents were prescribed antiarrhythmic 
drugs. Fifty percent of decedents received 1 antiepileptic 
drug , 33.7% received polytherapy with 2 to 3 AEDs, and 
7.5% received more than 3 AEDs.
Postmortem Examination
Autopsies were performed in 83 cases, refused in 
6, and unknown in 7. For the latter, it was not known 
whether an autopsy was performed as deaths oc-
curred at locations outside of Olmsted County, MN, 
and may not have been referred to the local medi-
cal examiner or coroner. Three autopsies were per-
formed at outside institutions in the vicinity of where 
death had occurred, and documentation indicated 
whether these were definite or definite- plus SUDEP 
cases.
The majority of autopsies were performed within 12 
to 24 hours of death, and 95.2% were complete (inter-
nal chest, abdomen, and neuropathological examina-
tions). Two cases were outside referrals for specialist 
neuropathologist input (ie, brain tissue sent for further 
analysis, with general autopsy performed at a local 
center).61
Of the 83 cases with autopsies, 63 were classed as 
definite, 13 as definite- plus, 6 as probable, and 1 as 
possible. The probable and possible cases either had 
limited autopsies, or the bodies had extensive decom-
position, or there were other possible contributors.
Variable Overall (n=96) Male sex (n=56) Female sex (n=40) P value
Focal, n (%) 8 (8) 5 (8.9) 3 (7.5) …
Focal and generalized, n (%) 11 (11) 6 (10.7) 5 (12.5) …
Unspecified, n (%) 5 (5) 3 (5.3) 2 (5.0) …
Duration of seizures 15.8±13.0 15.6±11.9 16.0±14.5 0.44
Mean±SD (range) y (0– 57) (0– 45) (0– 57)
ECG performed, n (%) 15 (15.6) … … …
Head magnetic resonance imaging/
computed tomography data available, n (%)
13 (13.5) … … …
Electroencephalography data available, 
n (%)
50 (52.1) … … …
ECG abnormal, n (%) 3 (3.1) … … …
Antiepileptic medications … … …
No or not compliant, n (%) 7 (8.8) 3 (6.1) 4 (12.9)
1 AED 40 (50.0) 23 (46.9) 17 (54.8)
2– 3 AED 27 (33.7) 17 (34.7) 10 (32.2)
>3 AED 6 (7.5) 6 (12.2) 0 (0.0)
Antiarrhythmic drugs 0 (0.0) … … …
Smoking status (former or current) 12 (12.5) … … …
Alcohol dependence 10 (10.4) … … …
AED indicates antiepileptic drugs; and SUDEP, sudden unexpected death in epilepsy.
*As per definition, SUDEP does not include cases of status epilepticus.
Table 1. (Continued)
Table 2. Characteristics of SUDEP Versus Non- SUDEP Deaths in PWE
Variable All (n=154) SUDEP (n=96) Non- SUDEP (n=58) 95% CI P value







Male sex 96 (62.3) 56 (57.5) 40 (69.0) 0.316– 1.524 0.1606
BMI 26.2±8.4 26.5±8.4 23.1±8.1 0.724– 3.215 0.2774
Multivariable logistical regression with outcome SUDEP vs non- SUDEP: Model 1: age and BMI 95% CI, 0.153– 6.515 (P=0.9); Model 2: age and sex 95% CI, 
0.295– 2.861 (P=0.99); Model 3: age, sex, and BMI 95% CI, 0.053– 18.71 (P=0.91). BMI indicates body mass index; PWE, people with epilepsy; and SUDEP, 
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General Findings
Most autopsies (92%) were performed without em-
balming. Five (6.0%) had extensive autolysis, prohib-
iting detailed examination. All reports contained a 
general statement on external findings such as height, 
weight, and evidence of decomposition. Signs of 
trauma were reported in 7 (8.4%) cases, and not re-
ported in 20 (24.1%). Regarding other external exam-
ination findings, only 8 (9.6%) had tongue or lip bite 
marks and 2 (2.4%) had petechiae possibly consistent 
with recent seizure activity. Only 1 (1.2%) had periorbi-
tal hematomas, possibly indicative of a fall and trauma 
to the face directly in the context of an arrest. Three 
(3.6%) had superficial burns with little other information 
provided (none of these cases had suspicion of deaths 
relating to fire). Seven (8.4%) had resuscitation marks, 
and of these, 3 were in witnessed SUDEP events, and 
the others were nonwitnessed deaths, but resuscita-
tion was attempted.
Neuropathology Findings
Thirty- four (41.0%) autopsies had a neuropathologist 
examine the nervous system (Table S3). Detailed find-
ings are in Data S1.
Regarding potential epileptogenic brain lesions, 6 
(7.3%) had arteriovenous malformations (2 with telangi-
ectasia). Other pathologies included cortical malforma-
tions in 10 (12.1%); focal cortical dysplasia in 4 (4.8%), 
and 1 (1.2%) case each of tuberous sclerosis, hemi-
megalencephaly, and grey matter heterotopia. The 
frequencies observed are similar to those reported in 
prior autopsy series.48– 51
Two cases had tumors, including a dysembryo-
plastic neuroepithelial tumor and an astrocytoma. 
Tumors in non- SUDEP cases included 4 meningio-
mas and an astrocytoma. Old surgical scars were 
noted in 4 (4.8%) of SUDEP cases and included prior 
surgical treatments for psychoses and tumor removal 
with the subsequent development of a focal epilepsy 
syndrome.
Gross changes to the hippocampus were reported 
in 14 (16.9%) of cases. Microscopic hippocampal 
sclerosis was reported in 8 (9.6%) of cases, of which 
6 were bilateral, and 1 case each for unilateral right 
sided and left sided. Two cases had both macro-
scopic and microscopic changes consistent with hip-
pocampal malrotational abnormality. In 61 (73.5%) of 
cases, neither microscopic nor macroscopic changes 
were reported.
Regarding potential secondary consequences of 
seizures, old traumatic injuries were identified in 2 
(2.4%), stroke in 3 (3.6%), mild cerebellar atrophy in 
6 (7.3%), and severe cerebellar atrophy in 3 (3.6%) of 
cases. These are lower than reported in other series, 
but in cases extending back to the 1960s and1970s, 
findings may have been missed or not commented 
upon. Acute neuronal injury was present in 31 (37.4%) 
of cases; was located in the subiculum in 4 cases (ex-
tensive in 3) and in the cortex and basal ganglia in 
11 cases; and its location was not described in the 
remainder.
Table 3. Circumstances of Death for 96 SUDEP Cases








Probable SUDEP 15 8 7
Possible SUDEP 5 2 3
Witnessed death, n (%)
Yes 15 (15.6) 9 (16.1) 6 (15.0)
No 56 (58.3) 36 (64.3) 20 (50.0)
Not documented 25 (26.1) 11 (19.6) 14 (35.)
Place of death
Home or work 53 (55.2) 32 (57.1) 21 (52.5)
Nursing facility 6 (6.3) 5 (8.9) 1 (2.5)
In hospital 8 (8.3) 3 (5.4) 5 (12.5)
Other 3 (3.1) 2 (3.6) 1 (2.5)
Unknown 26 (27.1) 14 (25.0) 12 (30.0)
Evidence of preceding seizure activity before SUDEP
Yes* 13 (13.5) 7 (12.5) 6 (15.0)
No 8 (8.3) 3 (5.4) 5 (12.5)
Unknown 75 (78.2) 46 (82.1) 29 (72.5)
Circumstances of death




1 (1.1) … …
During exercise 1 (1.1) … …
Nocturnal death 39 (40.6%) … …
Unknown 36 (37.4) … …
Position body was found in at time of death
Prone 25 (26.0) 15 (26.8) 10 (25.0)
Supine 6 (6.3) 4 (7.1) 2 (5.0)
Indeterminate 65 (67.7) 37 (66.1) 28 (70.0)
Location of body
Bed 19 (19.8) … …
Bedroom floor 4 (4.2) … …
Bathroom floor 4 (4.2) … …
Couch chair 2 (2.1) … …
Living room floor 6 (6.3) … …
No location 
documented
61 (63.5) … …
SUDEP indicates sudden unexpected death in epilepsy. Nocturnal death 
defined as occurring between 10:00 pm and 6:00 am.
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Cardiac Autopsy Findings
Thirteen (15.7%) had a cardiac pathologist examine 
the heart, or the full autopsy was performed by a car-
diac pathologist who was on general duty. The mean 
heart weight was 358±138 g for all cases, and when 
restricted to adults was 392±110 g (Table S4). These 
are higher than published reference values (nondis-
eased hearts mean 331±56.7, range 233– 383 g).62,63 
Five cases had left ventricular dilatation (mild in 4 and 
moderate in 1) and right ventricular dilatation (mild in 3 
and moderate in 2). None of the cases had a diagnosis 
of heart failure syndrome antemortem or at autopsy. 
Hypertrophy of the right ventricle was reported in 2 
(2.4%) and of the left ventricle in 14 (16.8%), which is 
higher than a previously reported frequency of 9.5%.51
The origin of the coronary arteries was reported in 
43 (51.8%) of patients, including 1 case that had an 
anomalous left coronary artery arising from the non-
coronary aortic sinus of Valsalva, which did not course 
within the aortic wall or between the aorta and pulmo-
nary artery (which are established scenarios for sud-
den death).
In 1 case of DrS, a 23- month- old Hispanic girl suf-
fered a witnessed asystolic sudden cardiac arrest and 
could not be resuscitated. The patient carried a familial 
pathogenic variant in SCN1A (exact details unavailable) 
and suffered from generalized and complex febrile 
seizures. Autopsy revealed an anomalous right coro-
nary artery arising from the left aortic sinus of Valsalva, 
which coursed between the aorta and pulmonary ar-
tery, but with no evidence of infarction. The autopsy 
was at an outside institution and categorized as a SCD 
event. We instead categorized this case as SUDEP- 
plus because it is plausible that the artery became 
compressed during a seizure or other stressful event. 
Witnesses of the arrest did not comment on the pres-
ence or absence of a seizure before the arrest.
Coronary artery atherosclerosis was present in 45 
(54.2%) of decedents (Table S5), although absence of 
coronary artery atherosclerosis was not specifically 
commented on in 28 (33.7%) of cases. The majority 
were grade 1 (1– 25% stenosed) or grade 2 (26– 50% 
stenosed). However, 13 cases had grade 3 (51– 75% 
stenosis) or grade 4 (75– 100%) stenosis, which are con-
sidered clinically relevant to be classified as coronary 
artery disease (CAD), but only grade 4 severe CAD are 
acute coronary syndromes. Six decedents had single- 
vessel CAD, 4 with 2- vessel, 1 with 3- vessel, and 2 
with 4- vessel CAD. No individuals had symptoms of 
angina, and none required any form of revasculariza-
tion. Only 1 case had subendocardial myocardial in-
farction on microscopic evaluation.
One case of definite SUDEP had mitral valve pro-
lapse without evidence of incompetence, which is as-
sociated with SCD.64 Three (3.6%) cases had bicuspid 
aortic valves. Two were detected at autopsy: 1 case 
was in a 16- year- old girl with fused right and left cusps 
and a shallow raphe, without evidence of stenosis or 
incompetence, who also had a left coronary artery 
arising from the noncoronary aortic sinus without an 
abnormal or high- risk course. The second case also 
had a competent bicuspid valve with fusion of the right 
and left cusps. The third case had coarctation of the 
aorta and had undergone bioprosthetic replacement of 
the bicuspid valve as well as aortic repair. The subject 
had no myocardial injury, aortic damage, or endocardi-
tis and died from a SUDEP event during sleep.
Two cases had slightly elevated blood alcohol lev-
els. Most AED levels were either subtherapeutic or 
normal, and only 1 case had elevated blood levels of 
carbamazepine. There were no documented concerns 
or evidence for suicide or a possible contribution of al-
cohol, drugs, or prescription medications to the cause 
of death (Table S6).
Consistency of Reports
We compared reporting to a standard set in an inter-
national guideline on investigation of deaths in PWE, 
which includes recommendations on information 
that should be included in SUDEP autopsy reports 
(Table S7). All reports had a brief history that was more 
detailed when a neuropathologist performed the en-
tire autopsy or a brain- only autopsy, and they tended 
to include details on seizure onset and type, as well 
as AED use. A full or partial autopsy was declined in 
6 cases, but a report was generated based on avail-
able information as required by the medical examiner 
or coroner.
Signs of asphyxiation were commented on 71 
(85.5%) of cases, and were seen in 4 (4.8%), all of 
which were classified as definite SUDEP as there was 
no evidence of another cause, suicide, or homicide. 
Only 1 pathologist commented on the presence of tu-
berous sclerosis, and there were no reported cases of 
Sturge- Weber or neurofibromatosis.
Sex- Based Differences
Using sex as a biological variable, we compared dif-
ferences between male and female cases (Table  1) 
and found no major differences specifically by region, 
age at epilepsy, age at SUDEP, duration of epilepsy, or 
mean number of AEDs.
Antemortem Genetic Testing
Five of the decedent SUDEP cases had a diagnosis of 
Dravet syndrome with pathogenic variants identified in 
SCN1A gene. There were no other known monogenic 
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Adjunct Postmortem Whole Exome 
Sequencing
Although blood was available on blood- spot cards for 
cases from 1997 onwards, the Minnesota State Health 
Department had destroyed these following a state 
Supreme Court decision that these samples cannot 
be stored or used for research without informed con-
sent.65 Furthermore, it has been routine to take whole 
blood at autopsy at Mayo Clinic Rochester since the 
1980s, but if no further investigation is conducted in 
the absence of suspicion of unnatural deaths, then 
these samples are destroyed after 2 years. Although 
formalin- fixed, paraffin- embedded tissue is available, 
the yield of WES is typically poor and hence this was 
not used. Therefore, WES was performed on only 11 
out of the 96 cases (6 White men, 1 White woman, 1 
Black man, 2 Black women, and 1 Hispanic man).
Yield of Ultrarare- NSVs in Sudden Death- 
Susceptibility Genes
Considering a dominant inheritance model, we identified 
18 ultrarare (MAF <0.00005), NSVs within the 166 sud-
den death- susceptibility genes in 6 (54.5%) of 11 SUDEP 
cases overall including 2 (66.7%) of 3 Black and 4 (57.1%) 
of 7 White decedents (Table 4). Furthermore, all 6- variant 
positive SUDEP cases hosted multiple ultrarare NSVs 
amid these 166 genes. Considering a recessive inherit-
ance model, homozygous or compound heterozygous 
variants were observed in 1 (9%) of 11 SUDEP cases. 
Following variant classification using the strict ACMG 
guidelines, none of the 19 variants observed in the 11 
SUDEP cases achieved either a “pathogenic” or “likely 
pathogenic” designation. Therefore, all variants were in-
stead classified as variants of uncertain significance.
Case 1
A 23- year- old White woman hosted 3 variants (p.412S- 
CACNB2, p.A1611V- MYH7, and p.A454T- SDHA). 
Although pathogenic variants in MYH7 are associ-
ated with hypertrophic cardiomyopathy, dilated car-
diomyopathy, and left ventricular noncompaction and 
pathogenic variants in SDHA have been associated 
with Leigh syndrome (severe movement disorder), 
pheochromocytoma, and paragangliomas, the car-
diovascular examination did not reveal any structural 
abnormalities, and there were no documented features 
consistent with Leigh syndrome, pheochromocytoma, 
or parangangliomas at autopsy.
Case 2
A 21- year- old Black woman hosted 4 ultrarare vari-
ants (p.T984A- SZT2, p.R1681H- SZT2, p.E25del- 
NEBL, p.R943Q- MYBPC3). Because parental DNA 
was unavailable, it is not known if the 2 SZT2 vari-
ants are in cis (same allele) or trans (opposite alleles). 
Pathogenic variants in SZT2 are associated with epi-
leptic encephalopathy. Pathogenic variants in NEBL 
and MYBPC3 have been associated with cardiomyo-
pathies. However, the patient had a limited autopsy, 
so it is not known if there were structural abnormali-
ties to the heart.
Case 3
A 48- year- old White man, who died during sleep, 
hosted 4 ultrarare variants (p.G1474E- RYR2, 
p.A756S- PRICKLE2, p.R900W- CNTAP2, and 
p.L451I- MIB1). Pathogenic variants in RYR2 are 
known to cause catecholaminergic polymorphic 
ventricular tachycardia. Cardiac events related to 
catecholaminergic polymorphic ventricular tachy-
cardia typically occur during exertion. Pathogenic 
variants in PRICKLE2 are associated with myoclonic 
epilepsy and in CNTNAP2 are associated with au-
tism and cortical dysplasia focal epilepsy syndrome. 
It is unknown whether the decedent had myoclonic 
epilepsy, but he had no features of autism or corti-
cal dysplasia focal epilepsy syndrome. Pathogenic 
variants in M1B1 are associated with left ventricular 
noncompaction; however, the decedent showed no 
overt features of left ventricular noncompaction on 
autopsy.
Case 4
A 67- year- old White man hosted an ultrarare variant in 
CLN8 (p.T163M- CLN8). Pathogenic variants in CLN8 
have been associated with Northern epilepsy and neu-
rodegenerative diseases typified by lipopigment accu-
mulation. Although this was not specifically evaluated 
at autopsy, the decedent’s medical records did not 
suggest these features.
Case 5
A 36- year- old White man with definite SUDEP, hosted 
3 ultrarare variants (p.V323M- CNTN2, p.V407L- 
ST3GAL5, and p.R761Q- CACNA1H). Pathogenic 
variants in CNTN2 and ST3GAL5 are associated with 
myoclonic epilepsy and epilepsy, respectively. The 
third variant, CACNA1H, is a gene associated with au-
tism and generalized absent seizures, which were not 
suggested by medical history.
Case 6
A 51- year- old Black man had coarctation of the 
aorta and a bicuspid aortic valve (both success-
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variants (p.P29S- GDNF, p.N68D- LAMA4, and 
p.A1389T- CACNA1H) as well as a homozygous 
p.R68H- CLCN2 variant.
Pathogenic variants in GDNF are associated with 
central hypoventilation syndrome. The victim of SUDEP 
died at night and was found in the prone position, which 
is typical of central hypoventilation syndrome. He also 
had a history of alcohol dependence, and these 2 con-
ditions may have contributed to SUDEP.
Pathogenic variants in CACNA1H are associated 
with autism and epilepsy, which the patient did not 
have. Pathogenic LAMA4 variants are associated with 
dilated cardiomyopathy. The autopsy did reveal moder-
ate left ventricular and right ventricular dilatation, which 
may reflect a dilated cardiomyopathy phenotype but 
equally could be because of prior coarctation repair 
and bicuspid aortic valve. The heart mass was 431 g 
(predicted 377 g for age and sex). It is unclear whether 
the aortic valve was stenotic, regurgitant, or both but 
did require surgery to repair. The valve and aorta had 
no other abnormalities at autopsy.
A homozygous p.R68H- CLCN2 variant was identi-
fied in SUDEP Case 6. The CLCN2 gene encodes for 
chloride voltage- gated channel 2. Heterozygous loss of 
function in CLCN2 mutations with pathogenic variants 
have been implicated previously in idiopathic general-
ized epilepsies. The p.R68H- CLCN2 was reported pre-
viously in 1 of 35 African individuals from a combination 
therapy trial or longitudinal survey to evaluate immu-
nological effects of malaria.66 Interestingly, p.R68H- 
CLCN2 was characterized functionally and shown to 
result in decrease steady state current and faster ac-
tivation of chloride voltage- gated channel 2 channels.
Cases 7– 11
These exhibited multiple variants, but with our strin-
gent cutoff, they did not meet criteria to be considered 
ultrarare (details are available on request).
DISCUSSION
This is one of the largest to date single- center US se-
ries of SUDEP cases. It has 5 important findings:
1. Decedents of SUDEP tend to be younger than 
decedents of other causes in PWE, with the ma-
jority being unwitnessed and found in the prone 
position, consistent with other reports.49– 51
2. Only 15% had an ECG performed, which may have 
missed coexistent channelopathies (long- QT syn-
drome or Brugada syndrome).
3. Older subjects of SUDEP tended to have bystander 
coronary artery disease (without plaque events, 
chronic ischemia, or myocardial infarction), which 
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4. The most frequent antemortem genetic abnormality 
was pathogenic variants in the SCN1A gene associ-
ated with DrS.
5. Prior blood- spot cards or postmortem blood sam-
ples had been discarded, thus eliminating a potential 
source to help elucidate genetic contributors and 
to illuminate mechanistic pathways contributing to 
SUDEP. Only 11 cases had sufficient samples to 
perform WES, which yielded no known pathogenic 
variants in arrhythmia, epilepsy, or respiratory- related 
genes but did identify 18 ultrarare NSV variants in 6 
cases.
Using the MSCDR, we identified 96 SUDEPs and 
58 non- SUDEPs, with the main difference being a 
younger age of death for the SUDEPs. The mean 
age of SUDEP decedents was 37.4 (±19.4) years, the 
young age at death underscoring the potential years 
of life lost in victims of SUDEP. Male sex was more 
frequent in both SUDEP and non- SUDEP groups, 
with no statistically significant difference. ECGs were 
performed in only 15 cases, one of whom had a pro-
longed QTc interval with known DrS. The sheer lack 
of ECG data in the evaluation of cases with seizures 
and epilepsy likely results in the missing of import-
ant abnormalities because ECG remains the optimal 
way to phenotype patients for identifying coexisting 
channelopathies.
Autopsies reports were available in 83 cases and 
demonstrated no abnormal findings in just over 50%. 
Several cases were reported as SCD or CAD based on 
the presence of bystander CAD, when macroscopic 
and microscopic examination did not reveal acute or 
old infarction, or evidence of acute ischemia. None of 
the cases had angina when living, nor complained of 
chest pain just before death. Pulmonary edema was 
a frequent finding, either overt or microscopic, and is 
consistent with other reports, possibly representing 
neurogenic pulmonary edema in the setting of SUDEP. 
Table S8 summarizes prior SUDEP series and our find-
ings. Autopsy reports since 2000 tended to be more 
systematic, including detailed cardiac and neuropatho-
logical evaluations.
One case of DrS had an anomalous coronary artery 
that coursed between the aorta and pulmonary artery, 
which could have become compressed during a sei-
zure, leading to sudden death. This could be classified 
as a SCD or SUDEP, and without an autopsy would 
not have been identified, underscoring the importance 
of comprehensive autopsy examination. There was an-
other case of an anomalous coronary artery with no 
abnormal course and therefore unlikely as a contribu-
tor to SUDEP. There were 3 (3.6%) cases of bicuspid 
aortic valve, which is higher than the population prev-
alence of 1%.67,68
Antemortem genetic testing was only performed in 
cases suspected of DrS. However, several cases had 
other physical features (eg, hypertelorism) and severe 
intellectual disabilities that could point toward undiag-
nosed genetic disease. Most cases had been evaluated 
for known inborn errors of metabolism and were neg-
ative. However, with the advent of personalized medi-
cine, these cases could be missed diagnostic odyssey 
cases, and identifying the genetic component could 
help shed light on SUDEP susceptibility in general. The 
frequency of known arrhythmia, seizures, and auto-
nomic and SCD- related genes in PWE are unknown. 
DrS is rare with an estimated incidence of 1:15 700 with 
most deaths occurring before 10  years of age nearly 
half because of SUDEP. Identifying DrS has implications 
for screening family members, providing prepregnancy 
counseling and possible prevention of SUDEP events 
using atropine as it can counter the parasympathetic 
hyperactivity observed in certain mice studies.69– 71
In a large study from Australia of 61 SUDEP cases, 
the most frequent variants identified were in long- QT 
syndrome genes (6 variants in KCNQ1 and KCNH2), 
followed by 2 pathogenic variants in epilepsy- related 
genes (DEPDC5 and PAFAH1B1).72 The authors re-
ported another 9 de novo variants described as patho-
genic based on in silico prediction tools, but these 
may be classified as variants of uncertain significance 
based on ACMG criteria.
In our study we used a cutoff of a MAF <0.00005 to 
identify ultrarare variants (versus 0.1% in the aforemen-
tioned study). We did not detect known pathogenic 
variants or potential pathogenic variants in DEPDC5 or 
PAFAH1B1. There are a number of possibilities for the 
observed low frequency of pathogenic variants, includ-
ing low sample size for postmortem WES population 
differences from founder effects and differing criteria 
for variant calling. We did not detect any differences in 
copy number variants in our study, which have been 
reported in cases of autism with dup(15) and a high 
frequency for SUDEP.
SUDEP shares many similarities with sudden infant 
death syndrome and sudden unexplained death syn-
dromes, including a high frequency of nocturnal deaths, 
being found in the prone position, negative autopsy 
findings, and a potential link to 5- hydroxytryptamine.73 
Most of our cases, where the position of the body was 
recorded, were prone.
CONCLUSIONS
This is the one of the largest single- center US series 
of SUDEP cases that used multisource ascertainment 
to determine the clinical profile, postmortem neuro-
pathological, cardiovascular, and pulmonary findings. 
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SCDs and were adjudicated to be SUDEPs given the 
past history of epilepsy. Many cases had bystander 
cardiovascular findings that were insufficient to lead to 
death.
Antemortem genetic findings revealed SCN1A 
variants to be the most frequent contributor. Adjunct 
postmortem WES was performed in 11 cases and did 
not identify any known pathogenic variants relating to 
arrhythmia, respiratory, and epilepsy genes. Eighteen 
ultrarare variants were discovered and classified as 
variants of uncertain significance as per ACMG criteria.
The lack of available adequate blood or tissue for 
genetic analysis in this large- scale series suggests 
that there remains a serious gap and urgent need for 
assembly of a large- scale, multicenter, cooperative 
prospective sudden death registry in PWE to yield ana-
lyzable blood and tissue. These could better illuminate 
the multiple possible respiratory, cardiac, and epilepsy 
specific pathophysiologic mechanisms underlying 
SUDEP, so that the tragic consequences of SUDEP 
might be prevented in the future.
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Neuropathology Findings: 34 (41.0%) autopsies had a neuropathologist examine the 
nervous system (Table S3). The mean mass of brains was 1329 (range 358-1720) g for all ages. 
The mean for decedents aged ≥ 18 years was 1384 (±147.6; range 1010-1720) g, which is similar 
to published normal reference ranges (mean 1407 g; range 1070-1767 g).61 Brain mass was 
higher for cases with documented swelling vs. those without, but the difference was not 
significant (p=0.14). Twenty-four (28.9%) had carotid artery stenosis: grade I in 19, grade II in 
2, grade III in 2, and grade IV in 1 case. Eight cases (9.6%) had hippocampal abnormalities, and 
absence of hippocampal abnormalities was documented in only 6 (7.3%), with no comment on 
the remaining 83.1%. Brain swelling was present in 12 (14.5%) cases, contusions in 4 (4.8%), 
and focal infarctions in 3 (3.6%).  
Microscopic evaluation of the myocardium was reported in 43 (51.8%) of cases. Focal 
fibrosis was observed in 14 (32.6%) of cases, and most were described as non-specific. In 2 
cases, fibrosis was considered to represent old myocarditis, and in another 2 cases there was 
patchy subendocardial fibrosis in a distribution inconsistent with infarction. Two cases had 
prominent but non-specific fatty infiltration of both the LV and RV. 
Pulmonary Autopsy Findings: Lung mass was reported in 59 cases, with 527 ± 199 g 
(range 115-950 g) for the right lung and 468 ± 177 g (95-880 g) for the left lung. When restricted 
to adults, this was 568 ± 167 g (range 225-950 g) for the right lung and 508 ± 146 g (range 220-
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was present in 27 (44.3%) of cases, and myocardial disease, renal disease, and heart failure were 
absent in all. Aspiration of gastric contents was noted in 5 (8.2%) of cases, 3 of which were 
classified as probable or possible cases of SUDEP. Two definite SUDEP cases had very 
aspiration, which often results from resuscitation or moving the body after death. 
Postmortem Toxicological Studies: Toxicological screening was specifically documented 
in 62 (74.7%) cases, and positive for 15. For cases in the late 1970s and early 1980s, 
toxicological screening became increasingly utilized, and by the 1990s was reported in all cases. 
The breadth of toxins became extended coinciding with the greater availability of mass 
spectrometry, and includes drugs of abuse, prescription medications (opioids and 
benzodiazepines), and salicylate and acetaminophen (for suspected suicide overdose cases). The 
AED levels focused on prescribed drugs, with levels usually within normal range or 
subtherapeutic concentrations.  
Height was recorded in 64 (77.1%) and weight in 65 (78.3%). Nourishment status was 
documented in 66 (79.5%) of cases, and reported as malnourished in 2 cases, both having a 
history of alcohol dependence. External injuries were reported on 63 (75.9%) of cases. Organs 
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Table S1. Hugo Gene Symbols of Candidate Genes Interrogated Following 
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Table S2. Multi-source ascertainment of SUDEP cases based on 
classification by Nashef et al. 








Definite SUDEP 63 63 63 0 57 
Definite SUDEP-
plus 
13 13 13 0 13 
Probable SUDEP 15 6 15 0 14 
Possible SUDEP 5 1 5 0 5 
Total 96 83 96 0 89 
SUDEP = Sudden Unexpected Death in Epilepsy Dow
nloaded from
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Table S3. Neuropathological Findings at Autopsy Examination for the 83 cases where 
autopsy reports are available. 




Heart examined by cardiac pathologist 13 (15.7) 45 (54.2) 25  (30.1) 
Brain examined by neuro-pathologist 34 (41.0) 28 (34.0) 21  (25.0) 
Body embalmed 7 (8.4) 54  (65.1) 22 (26.5) 
External 
Signs of trauma 7 (8.4) 56 (67.5) 20 (24.1) 
Tongue/lip biting 8 (9.6) 47 (56.6) 28 (33.7) 
Petechiae 2 (2.4) 40 (48.3) 41 (49.3) 
Periorbital hematoma 1 (1.2) 47 (56.6) 35 (42.2) 
Burns 3 (3.6) 67 (80.7) 13 (15.7) 
Resuscitation marks 7 (8.4) 47 (56.6) 29 (35.0) 
Macroscopic Brain Examination 
Hippocampal abnormality 2 (2.4) 6 (7.3) 75 (90.3) 
Mild brain swelling 12 (14.5) 44 (53.0) 27 (32.5) 
Contusions 4 (4.8) 49 (59.0) 30 (36.2) 
Evidence of infarction 3 (3.6) 48 (57.8) 32 (38.6) 
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Categories of lesions with potential for epileptogenicity 
AV malformations 6 (7.2) 47 (56.7) 30 (36.1) 
Malformations of cortical development 7 (11.7) -- -- 
FCD type IIB 4 (4.8) 42 (50.6) 37 (44.6) 
Tuberous sclerosis 1 (1.2) 46 (55.4) 36 (43.4) 
Hemimegalencephaly 1 (1.2) 45 (54.2) 37 (44.6) 
Grey matter heterotopia 1 (1.2) 45 (54.2) 37 (44.6) 
Polymicrogyria 0 (0.0) 45 (54.2) 38 (45.8) 
Ulegyria/perinatal cortical infarct (+ associated FCDIIId) 0 (0.0) 45 (54.2) 38 (45.8) 
Other FCD types (FCD I and mild MCD) 0 (0.0) 45 (54.2) 38 (45.8) 
Aicardi syndrome 0 (0.0) 45 (54.2) 38 (45.8) 
Tumor lesions 
DNT, oligodendroglioma, PA, meningioma, astrocytoma II, 
ganglioglioma 
2 (2.4) 45 (54.2) 36 (43.4) 
Old surgical scars 4 (4.8) 36 (43.4) 43 (51.8) 
Hippocampal sclerosis (confirmed on histology) 8 (9.6) 14 (16.9) 61 (73.5) 
Unilateral right 1 (1.2) -- -- 
Unilateral left 1 (1.2) -- -- 
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HIPMAL (macroscopic and microscopic) 2 (2.4) -- -- 
Secondary neuropathology (sequelae of seizures) -- -- 
Old traumatic brain injury/contusions 2 (2.4) 43 (51.8) 38 (45.8) 
Prior stroke 3 (3.6) 42 (50.6) 38 (45.8) 
Mild cerebellar atrophy (microscopic) 6 (7.3) 39 (46.9) 38 (45.8) 
Severe cerebellar atrophy (macroscopic) 3 (3.6) 42 (50.6) 38 (45.8) 
Evidence of Acute Neuronal Injury (AEN) 31 (37.4) 
CA1/subiculum 4 (4.8) 41 (49.4) 38 (45.8) 
Other location (cortex, basal ganglia) 11 (13.2) 34 (50.0) 38 (45.8) 
Extensive changes 3 (3.6) 42 (50.6) 38 (45.8) 
*Excludes aspiration
†Localized pathological lesions include causal as well as sequelae of seizures, however, excludes 
diffuse changes such as acute eosinophilic neurones 
MCD=Malformations of Cortical Development 
VM=Vascular malformations (and includes arterio-venous malformations and telangiectasias) 
FCD=Focal Cortical Dysplasia 
DNT=Dysembryoplastic Neuroepithelial Tumor 
PA=Pilocytic Astrocytoma 
HIPMAL=HIPpocampal MALrotational abnormality 
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Table S4. Cardiovascular and Pulmonary Findings at Autopsy. 
Cardiovascular 




Pericardial abnormalities 70 (84.3) 
Great vessel abnormalities 0 (0.0) 
Coronary artery dominance 
Right 51 
(78.5%) 
Co-dominant 2 (3.1) 
Left 3 (4.6) 
Unknown 9 (13.8) 
Normal course 44 
CAD Grade III-IV 
Myocardium 
Evidence of focal fibrosis 14 (32.6) Microscopy reported in 41 
cases 
Evidence of infarction 1 (2.3) 
Fatty infiltration 2 (4.7) 
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LVH 14 (16.9) 
RV dilatation 5 (6.0) 
RVH 2 (2.4) 
Pericardium abnormal 0 (0.0) 
Significant pericardial fluid 0 (0.0) 
Valves 
MV prolapse 1 (1.2) 
Mitral regurgitation 0 (0.0) 
Bicuspid aortic valve 3 (3.6) 
Aortic stenosis 0 
Aortic regurgitation 0 
Conduction System Disease 
SA node fibrosis 0 
AV node fibrosis 1 
Pulmonary Findings 
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Pulmonary edema/congestion* 27 (44.3) 
Aspiration of gastric contents? 5 (8.2) 
Tumors 0 (0.0) 
Pulmonary embolism 0 (0.0) 
CAD = Coronary Artery Disease 
SA node = Sino-Atrial node 
RVH = Right Ventricular Hypertrophy 
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RCA 15 27 9 3 1 28 
LCA 18 25 6 1 1 32 
LAD 11 24 10 7 4 27 
LCX 11 30 3 4 4 31 
Sum 55 106 28 15 10 118 




Two-vessel 4 (6.8) 
Three-vessel 1 (1.7) 
Four-vessel 2 (3.4) 
RCA = Right Coronary Artery 
LCA = Left Coronary Artery 
LAD = Left Anterior Descending Artery 
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Alcohol (Ethanol) 32 3 - 2 46 
Salicylate 24 1 - 0 58 
Acetaminophen 25 1 - 0 57 
Phenobarbital 27 2 2 0 52 
Phenytoin 8 4 3 0 53 
Valproate 23 3 0 0 57 
Lamotrigine 24 1 0 0 58 
Carbamazepine 25 1 1 1 55 
Hydroxycarbazepine 24 0 0 0 59 
Primidone 24 0 0 0 59 
Cocaine 30 - - - 53 
Cannabis 29 - - - 54 
Narcotic analgesics* 28 2 - 1 52 
Stimulant 
analgesics** 
30 - - - 53 
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Anti-depressants 18 1 - 1 63 
Environmental 
toxins 
24 - - - 59 
*Narcotic analgesics include codeine, methadone, pethidine, morphine, hydrocodone,
oxycodone, fentanyl 
**Stimulants Include Amphetamine, methamphetamine, MDMA (ecstasy), pseudoephedrine, 
fenfluramine, phentermine  
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Table S7. Consistency of Autopsy Reports. 
Recorded in 
n (%) 
Mean ± SD 
(range) 
History added to report 83 (100) 
Autopsy permission declined 6 
External examination 
Height  mean ± SD cm 64 (77.1) 164.8 ±20.7 
Weight mean ± SD kg 65 (78.3) 76.6 ± 35.2 
Nourishment status 66 (79.5) 
External injuries commented 63 (75.9) 
Body inspected by pathologist prior to evisceration? 13 (23.2) 
Signs of asphyxiation? 71 (85.5) 
Conditions associated with epilepsy 
Neuro-fibromatosis 0 (0.0) 
Sturge-Weber 0 (0.0) 
Tuberous sclerosis 1 (1.2) 
Full autopsy performed 79 (95.2) 
Blood collected for genetic studies 
Whole blood tubes 0 available 
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Brain (as per international guidelines)41,41 
Mass of brain 69 (83.1) 1329.4 
(±256.2) g 
Swelling 56 (67.5) 
Contusions 53 (63.9) 
Developmental abnormalities 53 (63.9) 
Mesial temporal (Ammon’s horn) sclerosis 51 (61.4) 
Cerebellar atrophy 52 (62.7) 
Coronal slices Unable to 
determine 
Microscopy commented 79 (95.2) 
Brain sites for histology 
a) Cingulate gyrus 0 (0) 
b) Hippocampus and parahippocampal gyrus
Right and Left
7 (8.4) 
c) Middle frontal gyrus 6 (7.2) 
d) Superior and middle temporal gyri 6 (7.2) 
e) Insula 4 (4.8) 
f) Caudate nucleus 4 (4.8) 
g) Putamen and globus pallidus 5 (6.0) 
h) Pons 6 (7.2) 
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j) Cerebellar hemisphere including dentate
nucleus
10 (12.0) 
k) Brainstem 40 (48.2) 
Skin collected for possible molecular studies 0 (0) 
Hair (for confirming AED compliance) 0 (0) 
Heart (as per sudden cardiac death guidelines)44 
Weight 71 (85.5) 
Pericardium 70 (84.3) 
Great vessels commented 58 (69.9) 
Coronary arteries 
Origin 43 (51.8) 
Dominance reported 65 (78.3) 
Course of epicardial coronary arteries 44 (53.0) 
CAD 56 (67.5) 
Myocardium and chambers 
Microscopy reported 43 (51.8) 
LV dilatation reported 56 (67.5) 
LV hypertrophy reported 59 (71.1) 
RV hypertrophy reported 59 (71.1) 
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Fatty infiltration reported 2 (2.4) 
Pericardium and effusion reported 59 (71.1) 
Valves 
MV prolapse reported 67 (80.7) 
Bicuspid aortic valve reported 62 (75.0) 
Tricuspid atresia reported 0 (0.0) 
Aortic stenosis reported 62 (75.0) 
Conduction system 
Examined 2 (2.4) 
SA node reported 2 (2.4) 
AV node reported 2 (2.4) 
Lungs 
Right lung mass 59 (71.1) 
Left lung mass 59 (71.1) 
Pulmonary edema/congestion 61 
Aspiration of gastric contents 61 (73.5) 
Tumors 0 (0.0) 
Pulmonary embolism 61 (73.5) 
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Table S8. Characteristics of Individual SUDEP Cases. 
Case 
number 
Sex Age at 
Death
SUDEP 
classification as per 
Nashef 2012






Rhythm QTc Comments ECG Position 











1 F 23 Definite Valproic acid Unknown Night Cerebral swelling, diffuse, mild; history of chronic seizure disorder
2 F 21 Definite Unknown Night Hx of seizure disorder and recent ethanol ingestion
3 M 48 Definite Phenytoin, carbamezapine Unknown Night Hx seizure disorder and chronic alcoholism
4 M 67 Definite Unknown Night Hx seizure disorder and coronary atherosclerosis
5 M 36 Definite Valproic Acid, phenytoin yes 76 Sinus rhythm 441 Normal ECG Unknown Day Hx GTCS 
6 M 51 Definite Topiramate, levetiracetam Prone Day Hx coarctation of aorta, aortic stenosis, bicuspid aortic valve, ascending aortic aneurysm
7 M 48 Definite Valproic acid, phenobarbital Prone Night Juvenile myoclonic epilepsy
8 M 38 Definite Phenobarbital Unknown Night Vascular malformations
9 F 11 Definite Lamotrigine, levetiracetam, diazepam Unknown Unknown Hx seizure disorder, ADHD
10 M 23 Definite  Diazepam, levetiracetam Unknown Day Hx alcohol and tetrahydrocannabinol abuse
11 M 46 Definitie-PLUS Gabapentin, valproic acid, diazepam Unknown Day Cardiomegaly, follicular adenoma of the thyroid gland
12 F 35 Definite Phenytoin, diazepam, valproic acid, phenobarbital Unknown Day Cerebral plasy
13 F 38 Definite Phenobarbital, diazepam Prone Night h/o focal and generalized seizures
14 M 26 Definite Carbamezapine, phenobarbitol Prone Day
15 M 49 Definite Phenobarbital, diazepam, phenytoin Unknown Unknown Temporal lobe seizures for 10+ years; hippocampal sclerisis
16 F 41 Definite Unknown Day h/o Sarcoidosis
17 F 31 Definite Phenytoin Prone Unknown
18 F 40 Definite Phenobarbital, phenytoin Unknown Day Hx GTCS 24yrs
19 M 17 Probable Valproic acid, phenobarbital, carbamezapine Unknown Night Cerebral palsy, mental retardation
20 M 7 Probable Carbamezapine yes Unknown Day Severe hydrocephalus; convulsive disorder,focal seizures
21 M 72 Possible Phenytoin, phenobarbital yes Sinus rhythm Anterior Myocardial infarctionUnknown Unknown Central arteriosclerosis and convulsive disorder, Hx of focal and generalized seizures
22 F 20 Probable Phenytoin Unknown Unknown Profound MR, motor deficits, spastic hemiplegia 
23 M 33 Probable Phenobarbital Unknown Unknown
24 F 32 Unknown Phenytoin, phenobarbital Unknown Unknown
25 M 27 Probable Phenobarbital, phenytoin yes 123 Sinus tachycardia Poor R wave progression Unknown Unknown Hx focal and generalized seizures
26 M 23 Probable Phenytoin, carbamezapine, phenobarbital yes 107 Sinus tachycardia 421 Left ventricular hypertrophyUnknown Night seizure/seizure disorder
27 M 31 Definite Phenobarbital yes 56 Sinus bradycardia 413 Normal ECG Prone Night Genrealized seizure disorder, posturally dependent obstructive sleep apnea, congenital heart disease (bicupsid aortic valve, ventricular septal defect)
28 M 30 Definite Phenytoin Prone Unknown History of several surgical procedures
29 F 79 Definite Phenytoin Prone Day Temporal lobe epilepsy; chronic bronchitis, bilateral pulmonary edema; microscopic bone marrow and fat emboli (focal)
30 F 26 Definite Phenobarbital, phenytoin, lamotrigine, valproic acid Prone Night Achondroplastic dwarfism, obesity
31 F 7 Definite Carbamezapine, valproic acid, phenobarbitol Unknown Night Hydrocephalus secondary to aqueductal stenosis (VP shunt in place), developmental abnormalities (partial agenesis of corpus callosum, absent septum pellucidum, hippocampal atrophy, partial agenesis of cingulate gyrus, Chiari Type 2 malformation, patchy moderate gliosis of left hippocampus predominantly CA4, subdural hematomas old and organizing)
32 F 15 Definite Phenobarbital, clonazepam Prone Night Generalized seizure disorder; previous infantile meningitis
33 F 51 Definite Carbamezapine, phenytoin Unknown Day
34 M 53 Definite Phenytoin, phenobarbital Prone Day nodular heterotopia, focal, right perventricular areaa at level of rostrum of corpus callpsum, tathke's cleft remnants
35 M 36 Definite Phenytoin, gabapentin Prone Day Marked bilateral hippocampal sclerosis without ventricular dilation; history of epileptic seizures since age 11 months
36 F 32 Definite Valproic acid Unknown Night History of post-transfusion hepatitis C; previous motor vehicle accident with severe closed head injury (operated); congestion and edema of both lungs (moderate to severe)
37 M 44 Unknown Lamotrigine Unknown Unknown
38 F 3 Probable Phenobarbital Unknown Day
39 F 18 Probable Unknown Unknown
40 F 34 Definite Diazepam, Phenytoin, Clonazepam, Valproic Acid Prone Day Intractable epilepsy, focal partial seizures
41 M 33 Definite Phenytoin, phenobarbital Unknown Night Mental retardation, Mood disorder
42 M 35 Unknown Alprazolam, lamotrigine Unknown Unknown
43 F 21 Definite Phenytoin, phenobarbital Unknown Day
44 F 74 Possible Phenytoin, Diazepam Unknown Day Idiopathic seizures, Immunosupression, Hypertension
45 F 52 Definite Phenytoin, phenobarbital Prone Night Multiple sclerosis, Ischemic heart disease
46 M 5 Definite Prone Day
47 M 38 Definite Prone Day Grand mal seizures, mental retardation
48 M 31 Definite Phenytoin Unknown Unknown Focal subarachnoid hemorrhages, focal ischemia of ascending colon
49 M 23 Definite Unknown Day
50 F 46 Definitie-PLUS yes Sinus rhythm Tall p waves Unknown Day Hypertension for 15yrs, possible alcohol abuse
51 M 39 Definite Phenytoin, Carbamazepine Prone Night Hx of seizure disorder,coronary atherosclerosis
52 F 45 Definitie-PLUS Phenytoin Unknown Day  Acute hemorrhagic pancreatitis, Hepatic cirrhosis, Old cerebral contusions, Blood alcohol 3092ug/ml
53 M 45 Definitie-PLUS Phenobarbital Unknown Day Coronary atherosclerosis
54 F 27 Definite Supine Day Severe pulmonary arteriosclerosis
55 F 17 non-SUDEP Phenytoin, phenobarbital Unknown Day Drowning
56 M 30 Definitie-PLUS Phenobarbital, carbamazepine Prone Night Combined focal and generalized seizures
57 F 73 Probable Unknown Day
58 M 41 Definite Unknown Unknown
59 F 18 Definite Phenobarbital,diazepam  yes 57 Atrial bradycardia 399 Prone Night Hx combined focal and generalized epilepsy
60 M 55 Possible Phenobarbital yes 57 Sinus bradycardia Unknown Night
61 F 43 Definite Phenytoin, Phenobarbital Prone Night Chronic paranoid schizophrenia
62 M 6 Definite Unknown Day Acute laryngotracheitis
63 M 11 Definite Unknown Day Prior vagals episodes, then seizures, then death
64 M 47 Definite Supine Night labelled as AMI (myocardium normal!) bystander CAD, known epilepsy
65 F 53 Definite Phenytoin Supine Day Cardiac dysrhythmia
66 M 21 Definite Phenytoin , Phenobarbital, Valproate, Carbamazepine Unknown Day Cerebral palsy with spastic dysplegia
67 M 42 Definite-PLUS Phenytoin Prone Night Chronic seizure disorder,Chronic hypertension
68 F 3 Definite Unknown Unknown Known Dravet with SCN1A DNM. Had 6 minute seizure, then arrested, taken to ITU, significant anoxic brain injury, lifesupport withdrawnSCN1A unknown mutation
69 F 2 Definite-PLUS Benzodiazepine, Topiramate Unknown Day Known Dravet had witnessed arrest without preceding seizure. Autopsy showed anomalous coronary artery. Unknown mutation
70 M 16 Definite Unknown Unknown Dravet syndrome Unknown mutation
71 F 17 Unknown Topiramate yes 106 Sinus arrhythmia 390 Normal ECG Unknown Unknown Aicardi Syndrome, outside sudden death. No autopsy available
72 M 8 Unknown Unknown Unknown Dravet syndrome SCNA1 p(Ala786Val) mutation
73 M 2 Definite Unknown Unknown Dravet syndrome, Developmental delay, SCN1A Arg101Gln mutation SCN1A p(Arg101Gln) mutation
74 F 68 Definitie-PLUS Unknown Day Hodgkin's lymphoma, nodular sclerosing type
75 F 56 Definite Phenytoin, Phenobarbital Unknown Day Hyperplastic marrow
76 M 38 Definite Phenytoin, Phenobarbital Unknown Night Hx GTCS, gross picture of suffocation at death
77 M 79 Probable Unknown Unknown
78 F 33 Probable Unknown Unknown
79 F 15 Probable Unknown Unknown
80 M 47 Definite-PLUS Phenytoin yes 92 Sinus rhythm 460 Left atrial enlargement, Left ventricular hypertrophyUnk own Day Pulmonary edema
81 F 53 Possible Phenytoin, Phenobarbital Unknown Unknown
82 M 46 Definite Phenytoin, Phenobarbital Unknown Unknown history of chronic alcoholism with chronic anxiety and inadequate personality, frontal lobotomy, convulsive disorder
83 M 65 Definite-PLUS yes Supine Day history of alcoholism , 
84 M 48 Possible yes 80 Sinus rhythm 360 Normal ECG Unknown Unknown
85 M 46 Definite Phenytoin, Phenobarbital yes Prone Day
86 F 32 Definite-PLUS Levitracetam Unknown Night
87 M 56 Definite Phenytoin Unknown Night Severe OSA and obesity too, prior PE (non on autopsy)
88 M 53 Definite-PLUS Supine Night
89 M 46 Definite-PLUS Valproate Prone Day long Hx GTCS, well-controlled, sudden death, bystander CAD
90 M 74 Definite-PLUS Unknown Day idiopathic GTCS, bystander CAD and non-specific fibrosis ? Old myocarditis
91 F 35 Definite Carbamazepine, Valproate Unknown Day Idiopathic GTCS
92 M 36 Definite Lamotrigine Unknown Unknown post-traumatic epilepsy
93 M 6 Definite Levetriracetam, Topiramate Unknown Day Microcephaly, probable under;lying genetic disorder. Sleep apnea
94 F 62 Definite-PLUS Carbamazepine Prone Day LVH, bystander CAD and patchy fibrosis
95 M 23 Definite Valproate Prone Day
96 F 50 Definite Prone Day EtOH precipitaed/related seizures, sudden death, no EtOH in blood
97 F 64 Possible Unknown Day EtOH precipitaed/related seizures, sudden death
98 M 19 Definite Carbamazepine, Phenytoin Unknown Day Niemann-pick disease
99 F 26 Definite Phenytoin yes 60 Sinus rhythm 480 Complete left bundle branch blockUnknown Day
100 M 23 Definite Carbamazepine Supine Day Tuberous sclerosis
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